These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 25707967)

  • 1. Quantitative pharmacology of denosumab in patients with bone metastases from solid tumors.
    Perez Ruixo JJ; Doshi S; Sohn W; Chow A
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S85-92. PubMed ID: 25707967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab for the treatment of bone metastases in advanced breast cancer.
    Casas A; Llombart A; Martín M
    Breast; 2013 Oct; 22(5):585-92. PubMed ID: 23759273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors.
    Lipton A; Balakumaran A
    Expert Rev Clin Pharmacol; 2012 Jul; 5(4):359-71. PubMed ID: 22943116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor.
    Rolfo C; Raez LE; Russo A; Reguart N; Campelo RG; Bronte G; Papadimitriou K; Silvestris F
    Expert Opin Biol Ther; 2014 Jan; 14(1):15-26. PubMed ID: 24161019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
    Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
    Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review.
    Sohn W; Simiens MA; Jaeger K; Hutton S; Jang G
    Br J Clin Pharmacol; 2014 Sep; 78(3):477-87. PubMed ID: 24548274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.
    Iranikhah M; Wilborn TW; Wensel TM; Ferrell JB
    Pharmacotherapy; 2012 Mar; 32(3):274-84. PubMed ID: 22392458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The clinical merit of anti-RANKL antibody denosumab in prostate cancer].
    Akaza H; Tsukamoto T; Suzuki K; Namiki M; Ozono S; Naitodept S
    Gan To Kagaku Ryoho; 2012 Feb; 39(2):207-12. PubMed ID: 22333629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.
    Lipton A; Steger GG; Figueroa J; Alvarado C; Solal-Celigny P; Body JJ; de Boer R; Berardi R; Gascon P; Tonkin KS; Coleman R; Paterson AH; Peterson MC; Fan M; Kinsey A; Jun S
    J Clin Oncol; 2007 Oct; 25(28):4431-7. PubMed ID: 17785705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab: benefits of RANK ligand inhibition in cancer patients.
    Lipton A; Jacobs I
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
    J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications.
    De Castro J; García R; Garrido P; Isla D; Massuti B; Blanca B; Vázquez J
    Clin Lung Cancer; 2015 Nov; 16(6):431-46. PubMed ID: 26264596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of bone metastasis by denosumab, the human monoclonal neutralizing antibody to RANKL].
    Yoneda T
    Nihon Rinsho; 2012 Dec; 70(12):2165-71. PubMed ID: 23259391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure.
    Body JJ; Lipton A; Gralow J; Steger GG; Gao G; Yeh H; Fizazi K
    J Bone Miner Res; 2010 Mar; 25(3):440-6. PubMed ID: 19653815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
    J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.
    Martin M; Bell R; Bourgeois H; Brufsky A; Diel I; Eniu A; Fallowfield L; Fujiwara Y; Jassem J; Paterson AH; Ritchie D; Steger GG; Stopeck A; Vogel C; Fan M; Jiang Q; Chung K; Dansey R; Braun A
    Clin Cancer Res; 2012 Sep; 18(17):4841-9. PubMed ID: 22893628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab for treatment of breast cancer bone metastases and beyond.
    Nangia JR; Ma JD; Nguyen CM; Mendes MA; Trivedi MV
    Expert Opin Biol Ther; 2012 Apr; 12(4):491-501. PubMed ID: 22348344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.
    Goessl C; Katz L; Dougall WC; Kostenuik PJ; Zoog HB; Braun A; Dansey R; Wagman RB
    Ann N Y Acad Sci; 2012 Aug; 1263():29-40. PubMed ID: 22831177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANKL inhibition in the treatment of bone metastases.
    Lipton A; Jun S
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):197-203. PubMed ID: 18685421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours.
    Gibiansky L; Sutjandra L; Doshi S; Zheng J; Sohn W; Peterson MC; Jang GR; Chow AT; Pérez-Ruixo JJ
    Clin Pharmacokinet; 2012 Apr; 51(4):247-60. PubMed ID: 22420579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.